26 October 2023
Pharma announces positive outcome following DSMB review reinforcing confidence in phase 3 on-going trial.
Maat Pharma announces that the DSMB unanimoulsy recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host Disease...